Design, Synthesis, and SAR of Covalent KIT and PDGFRA Inhibitors─Exploring Their Potential in Targeting GIST

Area of Science:

• Oncology
• Medicinal Chemistry
• Structural Biology

Background:

• Gastrointestinal stromal tumors (GIST) are common mesenchymal tumors driven by KIT/PDGFRA mutations.
• Tyrosine kinase inhibitors (TKIs) are standard GIST treatment but face resistance and toxicity.
• Developing novel therapies is crucial for improving outcomes in advanced GIST.

Purpose of the Study:

• To design and synthesize novel covalent TKIs targeting drug-resistant GIST mutations.
• To investigate structure-activity relationships (SAR) for mutant KIT and PDGFRA.
• To provide a structural basis for developing next-generation GIST therapies.

Main Methods:

• Structure-based drug design and chemical synthesis of covalent TKIs.
• In vitro biological evaluation of synthesized compounds against GIST cell lines.
• X-ray crystallography to determine the binding mode of inhibitors to PDGFRA.

Main Results:

• Identification of potent covalent TKIs effective against drug-resistant GIST mutations.
• Detailed SAR studies elucidating interactions with mutant KIT and PDGFRA.
• Determination of the first crystal structure of PDGFRA bound to a covalent inhibitor.

Conclusions:

• Covalent TKIs represent a promising strategy to overcome TKI resistance in GIST.
• Structure-based design is effective for developing targeted GIST therapies.
• These findings pave the way for safer and more effective treatments for advanced GIST.